• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hematology: Rituximab for follicular lymphoma: maintaining an open mind.

作者信息

Cheson Bruce D

出版信息

Nat Rev Clin Oncol. 2011 May;8(5):257-8. doi: 10.1038/nrclinonc.2011.35. Epub 2011 Mar 15.

DOI:10.1038/nrclinonc.2011.35
PMID:21403667
Abstract
摘要

相似文献

1
Hematology: Rituximab for follicular lymphoma: maintaining an open mind.血液学：利妥昔单抗治疗滤泡性淋巴瘤：保持开放的思维。
Nat Rev Clin Oncol. 2011 May;8(5):257-8. doi: 10.1038/nrclinonc.2011.35. Epub 2011 Mar 15.
2
Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.血液系统癌症：利妥昔单抗维持治疗可改善老年滤泡性淋巴瘤患者的预后。
Nat Rev Clin Oncol. 2013 Nov;10(11):607. doi: 10.1038/nrclinonc.2013.164. Epub 2013 Sep 3.
3
Maintenance rituximab should be considered for patients with follicular lymphoma.对于滤泡性淋巴瘤患者，应考虑使用利妥昔单抗进行维持治疗。
Clin Adv Hematol Oncol. 2014 Aug;12(8):541-3.
4
Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance.滤泡性淋巴瘤缓解后治疗的优化：利妥昔单抗维持治疗的疗效。
J Natl Compr Canc Netw. 2011 May;9(5):563-71. doi: 10.6004/jnccn.2011.0047.
5
Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies.滤泡性非霍奇金淋巴瘤维持利妥昔单抗治疗：事实与争议。
Leuk Lymphoma. 2012 May;53(5):770-8. doi: 10.3109/10428194.2011.628061. Epub 2011 Oct 24.
6
Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
BioDrugs. 2011 Oct 1;25(5):329-31. doi: 10.2165/11207200-000000000-00000.
7
Chemotherapy: maintenance rituximab for relapsed follicular lymphoma.化疗：利妥昔单抗维持治疗复发性滤泡性淋巴瘤。
Nat Rev Clin Oncol. 2010 Dec;7(12):677-8. doi: 10.1038/nrclinonc.2010.186.
8
Follicular lymphoma: watch and wait is watch and worry.滤泡性淋巴瘤：观察等待就是观察并担忧。
Lancet Oncol. 2014 Apr;15(4):368-9. doi: 10.1016/S1470-2045(14)70066-X. Epub 2014 Mar 4.
9
Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.利妥昔单抗二线维持治疗对滤泡性和套细胞淋巴瘤患者复发后的疗效
Leuk Lymphoma. 2014 Oct;55(10):2384-6. doi: 10.3109/10428194.2013.871280. Epub 2014 Mar 7.
10
Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma.利妥昔单抗维持治疗可消除滤泡性淋巴瘤患者中与循环淋巴瘤细胞相关的不良预后。
Blood. 2014 Apr 24;123(17):2740-2. doi: 10.1182/blood-2014-02-553693.

引用本文的文献

1
Trial Watch: Immunostimulatory cytokines.试验观察：免疫刺激细胞因子
Oncoimmunology. 2013 Jul 1;2(7):e24850. doi: 10.4161/onci.24850. Epub 2013 May 7.

本文引用的文献

1
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。
Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.
2
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.滤泡性淋巴瘤患者在 SAKK 35/98 试验中接受两种不同方案的单药利妥昔单抗治疗的长期随访。
J Clin Oncol. 2010 Oct 10;28(29):4480-4. doi: 10.1200/JCO.2010.28.4786. Epub 2010 Aug 9.
3
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.
利妥昔单抗维持治疗复发/难治性滤泡性非霍奇金淋巴瘤：EORTC 20981 期随机分组研究的长期结果。
J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.
4
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.在环磷酰胺、长春新碱和泼尼松治疗后使用利妥昔单抗维持治疗可延长晚期惰性淋巴瘤的无进展生存期：III期随机ECOG1496研究结果
J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.
5
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).对于复发和难治性滤泡性及套细胞淋巴瘤患者，在使用利妥昔单抗、氟达拉滨、环磷酰胺和米托蒽醌联合方案（R-FCM）进行挽救治疗后，采用利妥昔单抗维持治疗可显著延长缓解持续时间：德国低度淋巴瘤研究组（GLSG）一项前瞻性随机研究的结果。
Blood. 2006 Dec 15;108(13):4003-8. doi: 10.1182/blood-2006-04-016725. Epub 2006 Aug 31.
6
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.利妥昔单抗维持治疗可改善复发/难治性滤泡性非霍奇金淋巴瘤患者的临床结局，无论诱导治疗期间是否使用过利妥昔单抗：一项前瞻性随机3期组间试验的结果
Blood. 2006 Nov 15;108(10):3295-301. doi: 10.1182/blood-2006-05-021113. Epub 2006 Jul 27.
7
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.R-ICE方案与R-DHAP方案用于复发的CD20弥漫性大B细胞淋巴瘤（DLBCL）患者的随机III期研究，后续进行大剂量治疗并再次随机分组以决定是否接受利妥昔单抗维持治疗：CORAL研究的更新
Ann Oncol. 2006 May;17 Suppl 4:iv31-2. doi: 10.1093/annonc/mdj996.
8
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.最大化利妥昔单抗的治疗益处：惰性非霍奇金淋巴瘤患者的维持治疗与病情进展时再治疗——米妮·珀尔癌症研究网络的一项随机II期试验
J Clin Oncol. 2005 Feb 20;23(6):1088-95. doi: 10.1200/JCO.2005.12.191. Epub 2005 Jan 18.